The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antibody Drugs Market Research Report 2025
Synopsis
This report mainly focuses on antibody drugs market. Monoclonal Antibodies (IgMs) are antibodies that are made by identical immune cells, cloned from a single parent cell. They are therefore of constant structure and bind to the same foreign markers (called “antigens”). The technology behind the generation of monoclonal antibodies was discovered in 1972 by César Milstein and Georges Köhler – scientists at the Roche-funded Basel Institute for Immunology – who were later to win the Nobel Prize. Monoclonal antibodies revolutionized biological research and built the basis for the use of therapeutic antibodies in medicine and for the entire biotechnology industry.
The global Antibody Drugs market was valued at US$ 127990 million in 2023 and is anticipated to reach US$ 239390 million by 2030, witnessing a CAGR of 9.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antibody Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drugs.
Report Scope
The Antibody Drugs market size, estimations, and forecasts are provided in terms of sales volume (g) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Amgen
Bristol-Myers Squibb
F. Hoffmann-La Roche
Johnson & Johnson
AbbVie
Eli Lilly
Pfizer
Bayer
GlaxoSmithKline
Sanofi
Segment by Type
Monoclonal Antibodies
Antibody-Drug Conjugates
Polyclonal Antibodies
Segment by Application
Central Nervous System (CNS) Disorders
Cancers
Autoimmune Disorders
Cardiovascular Diseases
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antibody Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antibody Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
This report mainly focuses on antibody drugs market. Monoclonal Antibodies (IgMs) are antibodies that are made by identical immune cells, cloned from a single parent cell. They are therefore of constant structure and bind to the same foreign markers (called “antigens”). The technology behind the generation of monoclonal antibodies was discovered in 1972 by César Milstein and Georges Köhler – scientists at the Roche-funded Basel Institute for Immunology – who were later to win the Nobel Prize. Monoclonal antibodies revolutionized biological research and built the basis for the use of therapeutic antibodies in medicine and for the entire biotechnology industry.
The global Antibody Drugs market was valued at US$ 127990 million in 2023 and is anticipated to reach US$ 239390 million by 2030, witnessing a CAGR of 9.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antibody Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drugs.
Report Scope
The Antibody Drugs market size, estimations, and forecasts are provided in terms of sales volume (g) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Amgen
Bristol-Myers Squibb
F. Hoffmann-La Roche
Johnson & Johnson
AbbVie
Eli Lilly
Pfizer
Bayer
GlaxoSmithKline
Sanofi
Segment by Type
Monoclonal Antibodies
Antibody-Drug Conjugates
Polyclonal Antibodies
Segment by Application
Central Nervous System (CNS) Disorders
Cancers
Autoimmune Disorders
Cardiovascular Diseases
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antibody Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antibody Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Antibody Drugs Market Overview
1.1 Product Overview and Scope of Antibody Drugs
1.2 Antibody Drugs Segment by Type
1.2.1 Global Antibody Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Monoclonal Antibodies
1.2.3 Antibody-Drug Conjugates
1.2.4 Polyclonal Antibodies
1.3 Antibody Drugs Segment by Application
1.3.1 Global Antibody Drugs Market Value by Application: (2024-2030)
1.3.2 Central Nervous System (CNS) Disorders
1.3.3 Cancers
1.3.4 Autoimmune Disorders
1.3.5 Cardiovascular Diseases
1.4 Global Antibody Drugs Market Size Estimates and Forecasts
1.4.1 Global Antibody Drugs Revenue 2019-2030
1.4.2 Global Antibody Drugs Sales 2019-2030
1.4.3 Global Antibody Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Antibody Drugs Market Competition by Manufacturers
2.1 Global Antibody Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Antibody Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Antibody Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Antibody Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antibody Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antibody Drugs, Product Type & Application
2.7 Antibody Drugs Market Competitive Situation and Trends
2.7.1 Antibody Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antibody Drugs Players Market Share by Revenue
2.7.3 Global Antibody Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antibody Drugs Retrospective Market Scenario by Region
3.1 Global Antibody Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Antibody Drugs Global Antibody Drugs Sales by Region: 2019-2030
3.2.1 Global Antibody Drugs Sales by Region: 2019-2024
3.2.2 Global Antibody Drugs Sales by Region: 2025-2030
3.3 Global Antibody Drugs Global Antibody Drugs Revenue by Region: 2019-2030
3.3.1 Global Antibody Drugs Revenue by Region: 2019-2024
3.3.2 Global Antibody Drugs Revenue by Region: 2025-2030
3.4 North America Antibody Drugs Market Facts & Figures by Country
3.4.1 North America Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Antibody Drugs Sales by Country (2019-2030)
3.4.3 North America Antibody Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Antibody Drugs Market Facts & Figures by Country
3.5.1 Europe Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Antibody Drugs Sales by Country (2019-2030)
3.5.3 Europe Antibody Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antibody Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Antibody Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Antibody Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Antibody Drugs Market Facts & Figures by Country
3.7.1 Latin America Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Antibody Drugs Sales by Country (2019-2030)
3.7.3 Latin America Antibody Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antibody Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Antibody Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Antibody Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Antibody Drugs Sales by Type (2019-2030)
4.1.1 Global Antibody Drugs Sales by Type (2019-2024)
4.1.2 Global Antibody Drugs Sales by Type (2025-2030)
4.1.3 Global Antibody Drugs Sales Market Share by Type (2019-2030)
4.2 Global Antibody Drugs Revenue by Type (2019-2030)
4.2.1 Global Antibody Drugs Revenue by Type (2019-2024)
4.2.2 Global Antibody Drugs Revenue by Type (2025-2030)
4.2.3 Global Antibody Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Antibody Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Antibody Drugs Sales by Application (2019-2030)
5.1.1 Global Antibody Drugs Sales by Application (2019-2024)
5.1.2 Global Antibody Drugs Sales by Application (2025-2030)
5.1.3 Global Antibody Drugs Sales Market Share by Application (2019-2030)
5.2 Global Antibody Drugs Revenue by Application (2019-2030)
5.2.1 Global Antibody Drugs Revenue by Application (2019-2024)
5.2.2 Global Antibody Drugs Revenue by Application (2025-2030)
5.2.3 Global Antibody Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Antibody Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Antibody Drugs Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Amgen Antibody Drugs Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Bristol-Myers Squibb
6.3.1 Bristol-Myers Squibb Corporation Information
6.3.2 Bristol-Myers Squibb Description and Business Overview
6.3.3 Bristol-Myers Squibb Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Bristol-Myers Squibb Antibody Drugs Product Portfolio
6.3.5 Bristol-Myers Squibb Recent Developments/Updates
6.4 F. Hoffmann-La Roche
6.4.1 F. Hoffmann-La Roche Corporation Information
6.4.2 F. Hoffmann-La Roche Description and Business Overview
6.4.3 F. Hoffmann-La Roche Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 F. Hoffmann-La Roche Antibody Drugs Product Portfolio
6.4.5 F. Hoffmann-La Roche Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Corporation Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Johnson & Johnson Antibody Drugs Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 AbbVie
6.6.1 AbbVie Corporation Information
6.6.2 AbbVie Description and Business Overview
6.6.3 AbbVie Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 AbbVie Antibody Drugs Product Portfolio
6.6.5 AbbVie Recent Developments/Updates
6.7 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Eli Lilly Antibody Drugs Product Portfolio
6.7.5 Eli Lilly Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Corporation Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Pfizer Antibody Drugs Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Bayer
6.9.1 Bayer Corporation Information
6.9.2 Bayer Description and Business Overview
6.9.3 Bayer Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Bayer Antibody Drugs Product Portfolio
6.9.5 Bayer Recent Developments/Updates
6.10 GlaxoSmithKline
6.10.1 GlaxoSmithKline Corporation Information
6.10.2 GlaxoSmithKline Description and Business Overview
6.10.3 GlaxoSmithKline Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 GlaxoSmithKline Antibody Drugs Product Portfolio
6.10.5 GlaxoSmithKline Recent Developments/Updates
6.11 Sanofi
6.11.1 Sanofi Corporation Information
6.11.2 Sanofi Antibody Drugs Description and Business Overview
6.11.3 Sanofi Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Sanofi Antibody Drugs Product Portfolio
6.11.5 Sanofi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antibody Drugs Industry Chain Analysis
7.2 Antibody Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antibody Drugs Production Mode & Process
7.4 Antibody Drugs Sales and Marketing
7.4.1 Antibody Drugs Sales Channels
7.4.2 Antibody Drugs Distributors
7.5 Antibody Drugs Customers
8 Antibody Drugs Market Dynamics
8.1 Antibody Drugs Industry Trends
8.2 Antibody Drugs Market Drivers
8.3 Antibody Drugs Market Challenges
8.4 Antibody Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
